A multicenter, single-arm study using a modified faricimab treat-and-extend regimen in patients with macular edema due to central retinal vein occlusion: RVOSTAR study design protocol.

ABSTRACT:

Introduction

Anti-vascular endothelial growth factor (anti-VEGF) agents are generally considered to be the first line of therapy for macular edema due to retinal vein occlusion (RVO-ME). However, current anti-VEGF treatment regimens in Japan are unable to maintain long-term vision improvement, particularly in patients with central RVO-ME (CRVO-ME). Faricimab is a dual angiopoietin-2/VEGF inhibitor approved for the treatment of RVO-ME in Japan. The RVOSTAR study is being conducted to evaluate the long-term maintenance of vision outcomes with faricimab using a modified treat-and-extend (T&E) regimen in treatment-naïve Japanese patients with CRVO-ME or hemi-RVO-ME (HRVO-ME) and to assess the factors affecting visual acuity and treatment intervals.

Methods and design

RVOSTAR (Ja

SUBMITTER: Kondo M 

PROVIDER: S-EPMC12574838 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature